Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

33

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

33 results for “Drug Response Prediction”

Learn how ShareScore rates datasets ↗
zenodo40/100

Interpretable AI for drug response prediction

<p>This dataset contains input data needed to run the models evaluated in our study &quot;Interpretable deep learning architectures for improving drug response prediction: myth or reality?&quot;. The data required to run each model is organized into sub-folders, with the folder name being the corresponding model name. The data in &#39;model_agnostic_data&#39; is shared by all models. For details regarding each data file, please refer to the documentation (&#39;input_data_doc&#39;) included. The code for this study is available at&nbsp;<a href="https://github.com/Emad-COMBINE-lab/InterpretableAI_for_DRP">https://github.com/Emad-COMBINE-lab/InterpretableAI_for_DRP</a></p> <p>&nbsp;</p>

opencc-by-4.0Sep 2022View details →
zenodo40/100

Supplementary Data: Data Imbalance in Drug Response Prediction: Multi-Objective Optimization Approach in Deep Learning Setting

Open the record for dataset details and reuse information.

opencc-by-4.0Sep 2024View details →
zenodo36/100

Predicting transcriptional responses to novel chemical perturbations using deep generative model for drug discovery

<p>Understanding transcriptional responses to chemical perturbations is central to drug discovery, but exhaustive experimental screening of diseasecompound combinations is unfeasible. To overcome this limitation, here we introduce PRnet, a perturbation-conditioned deep generative model that predicts transcriptional responses to novel chemical perturbations that have never experimentally perturbed at bulk and single-cell levels. Evaluations indicate that PRnet outperforms alternative methods in predicting responses across novel compounds, pathways, and cell lines. PRnet enables gene-level response interpretation and in-silico drug screening for diseases based on gene signatures. PRnet further identifies and experimentally validates novel compound candidates against small cell lung cancer and colorectal cancer. Lastly, PRnet generates a large-scale integration atlas of perturbation profiles, covering 88 cell lines, 52 tissues, and various compound libraries. PRnet provides a robust and scalable candidate recommendation workflow and successfully recommends drug candidates for 233 diseases. Overall, PRnet is an effective and valuable tool for gene-based therapeutics screening.</p>

opencc-by-4.0Oct 2024View details →
zenodo36/100

Predicting cancer prognosis and drug response from the tumor microbiome

<p>Tumor gene expression is predictive of patient prognosis in some cancers. However, RNA-seq and whole genome sequencing data contain not only reads from host tumor and normal tissue, but also reads from the tumor microbiome, which can be used to infer the microbial abundances in each tumor. Here, we show that tumor microbial abundances, alone or in combination with tumor gene expression data, can predict cancer prognosis and drug response to some extent &ndash; microbial abundances are significantly less predictive of prognosis than gene expression, although remarkably, similarly as predictive of drug response, but in mostly different cancer-drug combinations. Thus, it appears possible to leverage existing sequencing technology, or develop new protocols, to obtain more non-redundant information about prognosis and drug response from RNA-seq and whole genome sequencing experiments than could be obtained from tumor gene expression or genomic data alone.</p>

opencc-by-4.0Aug 2021View details →
zenodo36/100

A systematic assessment of deep learning methods for drug response prediction: from in-vitro to clinical application

<p>https://github.com/LihongLab/Suppl-data-Benchmark</p> <p>## GDSC dataset</p> <p>**Table S3.** GDSC gene expression profiles for 966 cancer cell lines, where each column represents a cell line in the form of its name and tissue collection site, and each row represents a gene in the form of the HGNC symbol.</p> <p>&nbsp;</p> <p>**Table S4.** GDSC gene mutation profiles for 966 cancer cell lines, where each column represents a cell line in the form of its name and tissue collection site, and each row represents a gene in the form of the HGNC symbol. The wild type is coded as 1 and the wild type as 0.</p> <p>&nbsp;</p> <p>**Table S5.** GDSC copy number variation profiles for 966 cancer cell lines, where each column represents a cell line in the form of its name and tissue collection site, and each row represents a gene in the form of the HGNC symbol. The copy-neutral is coded as 0 and the deletion or amplification as 1.</p> <p>&nbsp;</p> <p>**Table S6.** GDSC drug response data for 966 cancer cell lines and 282 drugs in the form of the natural logarithm of the IC50 readout. The first column shows the cell line name and tissue collection site, the second column shows the drug name, and the third column shows the drug response readout.</p> <p>&nbsp;</p> <p>**Table S7.** GDSC annotations for 282 drugs include drug name, PubChem CID, PubChem canonical SMILES, Rdkit canonical SMILES, Target Pathway, standard deviation, bimodality coefficient and density coverage.</p> <p>## TCGA dataset</p> <p>**Table S8.** TCGA gene expression profiles, where each column represents a patient in the form of TCGA patient ID, and each row represents a gene in the form of the HGNC symbol.</p> <p>&nbsp;</p> <p>**Table S9.** TCGA gene mutation profiles, where each column represents a patient in the form of TCGA patient ID, and each row represents a gene in the form of the HGNC symbol. The wild type is coded as 1 and the wild type as 0.</p> <p>&nbsp;</p> <p>**Table S10.** TCGA copy number variation profiles, where each column represents a patient in the form of TCGA patient ID, and each row represents a gene in the form of the HGNC symbol. The copy-neutral is coded as 0 and the deletion or amplification as 1.</p> <p>&nbsp;</p> <p>**Table S11.** TCGA clinical response data. The first column shows the TCGA patient ID, the second column shows the drug name, the third column shows the clinical response category, the fourth column shows the cancer type, and the last column shows the clinical label as responder or non-responder.</p>

opencc-by-4.0Sep 2022View details →
zenodo36/100

A systematic assessment of deep learning methods for drug response prediction: From in vitro to clinical applications

<p>## GDSC dataset</p> <p>**GDSC_EXP.csv** GDSC gene expression profiles for 966 cancer cell lines, where each column represents a cell line in the form of its name and tissue collection site, and each row represents a gene in the form of the HGNC symbol.</p> <p>&nbsp;</p> <p>**GDSC_MUT.csv** GDSC gene mutation profiles for 966 cancer cell lines, where each column represents a cell line in the form of its name and tissue collection site, and each row represents a gene in the form of the HGNC symbol. The wild type is coded as 1 and the wild type as 0.</p> <p>&nbsp;</p> <p>**GDSC_CNV.csv** GDSC copy number variation profiles for 966 cancer cell lines, where each column represents a cell line in the form of its name and tissue collection site, and each row represents a gene in the form of the HGNC symbol. The copy-neutral is coded as 0 and the deletion or amplification as 1.</p> <p>&nbsp;</p> <p>**GDSC_DR.csv** GDSC drug response data for 966 cancer cell lines and 282 drugs in the form of the natural logarithm of the IC50 readout. The first column shows the cell line name and tissue collection site, the second column shows the drug name, and the third column shows the drug response readout.</p> <p>&nbsp;</p> <p>**GDSC_DrugAnnotation.csv** GDSC annotations for 282 drugs include drug name, PubChem CID, PubChem canonical SMILES, Rdkit canonical SMILES, Target Pathway, standard deviation, bimodality coefficient and density coverage.</p> <p>## TCGA dataset</p> <p>**TCGA_EXP.csv** TCGA gene expression profiles, where each column represents a patient in the form of TCGA patient ID, and each row represents a gene in the form of the HGNC symbol.</p> <p>&nbsp;</p> <p>**TCGA_MUT.csv** TCGA gene mutation profiles, where each column represents a patient in the form of TCGA patient ID, and each row represents a gene in the form of the HGNC symbol. The wild type is coded as 1 and the wild type as 0.</p> <p>&nbsp;</p> <p>**TCGA_CNV.csv** TCGA copy number variation profiles, where each column represents a patient in the form of TCGA patient ID, and each row represents a gene in the form of the HGNC symbol. The copy-neutral is coded as 0 and the deletion or amplification as 1.</p> <p>&nbsp;</p> <p>**TCGA_DR.csv** TCGA clinical response data. The first column shows the TCGA patient ID, the second column shows the drug name, the third column shows the clinical response category, the fourth column shows the cancer type, and the last column shows the clinical label as responder or non-responder.</p> <p>## PMID17185464 (Bortezomib) dataset</p> <p>**PMID17185464_EXP.csv** Bortezomib clinical trial gene expression profiles, where each column represents a patient in the form of patient ID, and each row represents a gene in the form of the HGNC symbol.</p> <p>**PMID17185464_DR.csv** Bortezomib clinical trial clinical response data. The first column shows the TCGA patient ID, the second column shows the drug name, the third column shows the clinical response category, and the last column shows the clinical label as responder or non-responder (NR: Non-responder, R: Responder).</p>

opencc-by-4.0Oct 2022View details →
zenodo32/100

MOLI: multi-omics late integration with deep neural networks for drug response prediction

<p>Harmonized data used in &quot;MOLI: multi-omics late integration with deep neural networks for drug response prediction&quot;, 2019,&nbsp;<em>Bioinformatics&nbsp;</em><a href="https://academic.oup.com/bioinformatics/article/35/14/i501/5529255">https://academic.oup.com/bioinformatics/article/35/14/i501/5529255</a>.&nbsp;<br> CNA.tar.gz contains CNA profiles with non-integer estimates of copy number, e.g. log-ratios. Please use binarized CNA profiles&nbsp;(CNA_binary.tar.gz) to replicate the results described in the paper.&nbsp;</p> <p><br> All raw data were obtained from open sources:<br> - https://www.cancerrxgene.org/<br> - ArrayExpress https://www.ebi.ac.uk/arrayexpress/<br> - Firehose Broad GDAC http://gdac.broadinstitute.org/runs/stddata__2016_01_28/data/<br> - Supplementary of Gao et al., 2015 https://www.nature.com/articles/nm.3954</p> <p>Gene symbols were mapped to&nbsp;Entrez Gene IDs. Data preprocessing is described in detail in supplementary materials. The code is available at&nbsp;<a href="https://github.com/hosseinshn/MOLI/tree/master/preprocessing_scr">https://github.com/hosseinshn/MOLI/tree/master/preprocessing_scr</a>.</p>

opencc-by-4.0Sep 2019View details →
zenodo32/100

Clinical Dataset for the Paper 'Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis'

<p>This dataset accompanies the manuscript titled "Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis." It includes clinical data used for training and evaluating the machine learning models described in the paper. The dataset contains baseline clinical data of 154 RA patients who were treated with bDMARDs. The labels for remission, and effectiveness (remission and low disease activity) were applied after a 6-month follow-up based on EULAR criteria on DAS28ESR. The sustained effectiveness label indicates maintaining effectiveness within 6 months after initially achieving effectiveness.</p> <p><strong>Crossponder Authors:</strong></p> <ul> <li>Fatemeh Salehi (email: <a rel="noreferrer">fatemeh.salehihafshejni@fau.de</a>)</li> </ul>

opencc-by-4.0Jun 2024View details →
ClinicalTrials.gov32/100

Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )

ClinicalTrials.gov study NCT02896985. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting

ClinicalTrials.gov study NCT06792149. IPD Sharing: YES. Countries: 1. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Computation Prediction of Drug Response Based on Omics Data

ClinicalTrials.gov study NCT05833802. IPD Sharing: NO. Countries: 1. Publications: 3.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Variability of Sulfotransferase 1A1 Activity in Humans: an Approach to Improve Predictive Drug Response - Part I: Analysis of Intraindividual Variation in Healthy Adults

ClinicalTrials.gov study NCT03182595. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
geo24/100

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers

GEO Series GSE232173. Homo sapiens. 24 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenAug 2023View details →
geo24/100

Emergent gene expression responses to drug combinations predict higher-order drug interactions

GEO Series GSE138256. Saccharomyces cerevisiae BY4741. 238 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenOct 2019View details →
geo24/100

Patient adipose stem cell-derived adipocytes reveal genetic variation that predicts anti-diabetic drug response

GEO Series GSE115421. Homo sapiens. 62 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenJan 2019View details →
geo24/100

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

GEO Series GSE199336. Homo sapiens. 184 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMay 2022View details →
geo24/100

Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models (I)

GEO Series GSE69211. Mus musculus. 28 samples. Type: Expression profiling by array.

openGEO-OpenSep 2015View details →
geo24/100

Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models (II)

GEO Series GSE69213. Mus musculus. 7 samples. Type: Expression profiling by array.

openGEO-OpenSep 2015View details →
ClinicalTrials.gov24/100

TMS Combined With EEG/EMG as a Biomarker Predicting Antiepileptic Drug Response

ClinicalTrials.gov study NCT05278221. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

Brain Slice Explants to Predict Drug Response in Brain Tumors

ClinicalTrials.gov study NCT05978557. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.